1 / 5

ORIGIN trial (Outcome Reduction with an Initial Glargine INtervention)

Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1. ORIGIN trial (Outcome Reduction with an Initial Glargine INtervention).

rachel-puckett
Download Presentation

ORIGIN trial (Outcome Reduction with an Initial Glargine INtervention)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cardiovascularoutcome in patients withdysglycemiawithdailysupplementation of n-3 fatty acids1 ORIGIN trial (Outcome Reduction with an Initial Glargine INtervention) 1- The ORIGIN Trial Investigators. n-3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309-318.

  2. 15 392 Patients screened for eligibility 1627 Excluded: 322 Did not meet inclusion criteria 10 Declined to participate 1295 Had other reasons 13 765 Patients included in run-in 1154 Excluded: 356 Had ineligible plasma glucose 42 Were ineligible for other reasons 397 Were nonadherent in run-in 264 Withdrew consent 95 Had other reasons 12 611 Patients randomized 6319 Received n-3 fatty acids 6292 Received placebo 38 Excluded by health authorities 37 Excluded by health authorities 6208 Had known outcome status 47 Did not have final outcome status 18 Withdrew consent 20 Did not give consent to extension 9 Were lost to follow-up 6220 Had known outcome status 61 Did not have final outcome status 14 Withdrew consent 38 Did not give consent to extension 9 Were lost to follow-up 6281 Were included in the analysis 6255 Were included in the analysis Median follow-up: 6.2 years

  3. Influence of the n-3 fattyacidregimen on mortality % %

  4. Influence of the n-3 fattyacidregimen on cardiovascularevents % %

  5. Conclusions Daily 1-g dose of n-3 fattyacidsdid not preventdeath or anycardiovascularoutcome in hyperglycemic or diabetic patients withhighcardiovascularriskcomparedwith placebo

More Related